Thomas M. Habermann

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford et al. · Nature Medicine · 2018 · 1.9K citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Molecular Subtypes +8

Association of Perceived Medical Errors With Resident Distress and Empathy

Colin P. West, Mashele Huschka, Paul J. Novotny et al. · JAMA · 2006 · 1.4K citations

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Thomas M. Habermann, Edie Weller, Vicki A. Morrison et al. · Journal of Clinical Oncology · 2006 · 1.4K citations · Full text

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +5

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Jens G. Lohr, Petar Stojanov, Michael S. Lawrence et al. · Proceedings of the National Academy of Sciences · 2012 · 977 citations · Full text